You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》亚盛医药(06855.HK)料核心药物最快於2021年商业化(更正)
阿思达克 10-28 10:25

亚盛医药(06855.HK)公布在主板上市计划,联合创始人兼首席执行官杨大俊在记者会上表示,公司有8项处临床阶段的小分子候选药物,其中核心药物「HQP1351」的关键二期临床试验持续,公司计划明年为该药申请上市注册许可,如临床数据满意及获监管批准,最快可於2021年商业化。

公司是次上市引入中生制药(01177.HK)作为基石投资者,认购相当於2,000万美元股份。杨大俊称未来与中生制药有很多机会探讨合作空间,但是次对方是次投资者身份入股。

对於公司此前打算在美国上市,及有否考虑在内地科创板上市,他指2017年初公司作B轮融资後曾考虑在美国上市,但其後香港联交所容许未录盈利生物科技企业在港上市,公司认为政策利好,香港市场亦符合公司特点,因此选择在港上市。杨氏提到,公司目前希望将研发做好及专注香港市场,但未来也不排除寻找符合公司发展需求的资本市场机会。

另外,被问及是次集资规划仅约4亿元,与公司完成C轮融资後的约60亿元估值有差距,首席财务官张苏指公司C轮融资集资额较大,截至今年6月仍有约7亿元人民币资金,是次集资规模是考虑了公司自身需求及药物管线进展等因素。

(更正:2019-10-16 11:30:12 《新股消息》亚盛医药

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account